RU2012129839A - COMBINATION OF THEOBROMIN WITH DECONGESTANT AND ITS APPLICATION FOR TREATMENT OF COUGH - Google Patents

COMBINATION OF THEOBROMIN WITH DECONGESTANT AND ITS APPLICATION FOR TREATMENT OF COUGH Download PDF

Info

Publication number
RU2012129839A
RU2012129839A RU2012129839/15A RU2012129839A RU2012129839A RU 2012129839 A RU2012129839 A RU 2012129839A RU 2012129839/15 A RU2012129839/15 A RU 2012129839/15A RU 2012129839 A RU2012129839 A RU 2012129839A RU 2012129839 A RU2012129839 A RU 2012129839A
Authority
RU
Russia
Prior art keywords
decongestant
treatment
cough
pseudoephedrine
composition according
Prior art date
Application number
RU2012129839/15A
Other languages
Russian (ru)
Other versions
RU2564904C2 (en
Inventor
Джон Брю
Робин Марк Баннистер
Original Assignee
Байокоупи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байокоупи Лимитед filed Critical Байокоупи Лимитед
Publication of RU2012129839A publication Critical patent/RU2012129839A/en
Application granted granted Critical
Publication of RU2564904C2 publication Critical patent/RU2564904C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Средство, содержащее теобромин и деконгестант в виде комбинированного препарата для одновременного, последовательного или отдельного применения при лечении.2. Средство по п.1, которое предназначено для лечения кашля.3. Средство по п.1, где деконгестант выбран из эфедрина, левметамфетамина, нафазолина, оксиметазолина, фенилэфрина, фенилпропаноламина, пропилгекседрина, псевдоэфедрина, синефрина и тетрагидрозолина.4. Средство по п.3, где деконгестант представляет собой псевдоэфедрин.5. Средство по любому из пп.1-4, где деконгестант должен вводиться в дозе от 0,1 до 30 мг/кг/день.6. Фармацевтическая композиция, содержащая теобромин и деконгестант.7. Композиция по п.6, где деконгестант выбран из эфедрина, левметамфетамина, нафазолина, оксиметазолина, фенилэфрина, фенилпропаноламина, пропилгекседрина, псевдоэфедрина, синефрина и тетрагидрозолина.8. Композиция по п.7, где деконгестант представляет собой псевдоэфедрин.9. Композиция по любому из пп.6-8, где деконгестант должен вводиться в дозе от 0,1 до 30 мг/кг/день.10. Применение фармацевтической композиции по любому из пп.6-9 для получения лекарственного средства для лечения кашля.11. Способ лечения кашля, включающий этап введения фармацевтической композиции по любому из пп.6-9.1. An agent containing theobromine and decongestant in the form of a combined preparation for simultaneous, sequential or separate use in treatment. The tool according to claim 1, which is intended for the treatment of cough. The agent according to claim 1, wherein the decongestant is selected from ephedrine, levmetamphetamine, naphazoline, oxymethazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, synephrine and tetrahydrozoline. The agent of claim 3, wherein the decongestant is pseudoephedrine. The agent according to any one of claims 1 to 4, wherein the decongestant should be administered in a dose of 0.1 to 30 mg / kg / day. A pharmaceutical composition containing theobromine and decongestant. 7. The composition of claim 6, wherein the decongestant is selected from ephedrine, levmethamphetamine, naphazoline, oxymethazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, synephrine and tetrahydrozoline. The composition of claim 7, wherein the decongestant is pseudoephedrine. A composition according to any one of claims 6 to 8, wherein the decongestant should be administered in a dose of 0.1 to 30 mg / kg / day. The use of the pharmaceutical composition according to any one of claims 6 to 9 for the manufacture of a medicament for the treatment of cough. 11. A method for treating cough, comprising the step of administering a pharmaceutical composition according to any one of claims 6 to 9.

Claims (11)

1. Средство, содержащее теобромин и деконгестант в виде комбинированного препарата для одновременного, последовательного или отдельного применения при лечении.1. A tool containing theobromine and decongestant in the form of a combined preparation for simultaneous, sequential or separate use in treatment. 2. Средство по п.1, которое предназначено для лечения кашля.2. The tool according to claim 1, which is intended for the treatment of cough. 3. Средство по п.1, где деконгестант выбран из эфедрина, левметамфетамина, нафазолина, оксиметазолина, фенилэфрина, фенилпропаноламина, пропилгекседрина, псевдоэфедрина, синефрина и тетрагидрозолина.3. The tool according to claim 1, where the decongestant is selected from ephedrine, levmethamphetamine, naphazoline, oxymetazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, synephrine and tetrahydrozoline. 4. Средство по п.3, где деконгестант представляет собой псевдоэфедрин.4. The tool according to claim 3, where the decongestant is pseudoephedrine. 5. Средство по любому из пп.1-4, где деконгестант должен вводиться в дозе от 0,1 до 30 мг/кг/день.5. The tool according to any one of claims 1 to 4, where the decongestant should be administered in a dose of from 0.1 to 30 mg / kg / day. 6. Фармацевтическая композиция, содержащая теобромин и деконгестант.6. A pharmaceutical composition comprising theobromine and decongestant. 7. Композиция по п.6, где деконгестант выбран из эфедрина, левметамфетамина, нафазолина, оксиметазолина, фенилэфрина, фенилпропаноламина, пропилгекседрина, псевдоэфедрина, синефрина и тетрагидрозолина.7. The composition according to claim 6, where the decongestant is selected from ephedrine, levmetamphetamine, naphazoline, oxymethazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, synephrine and tetrahydrozoline. 8. Композиция по п.7, где деконгестант представляет собой псевдоэфедрин.8. The composition according to claim 7, where the decongestant is pseudoephedrine. 9. Композиция по любому из пп.6-8, где деконгестант должен вводиться в дозе от 0,1 до 30 мг/кг/день.9. The composition according to any one of paragraphs.6-8, where the decongestant should be administered in a dose of from 0.1 to 30 mg / kg / day. 10. Применение фармацевтической композиции по любому из пп.6-9 для получения лекарственного средства для лечения кашля.10. The use of the pharmaceutical composition according to any one of claims 6 to 9 for the manufacture of a medicament for the treatment of cough. 11. Способ лечения кашля, включающий этап введения фармацевтической композиции по любому из пп.6-9. 11. A method for treating cough, comprising the step of administering a pharmaceutical composition according to any one of claims 6 to 9.
RU2012129839/15A 2009-12-14 2010-12-14 Theobromine-decongestant combination and application thereof for treating cough RU2564904C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0921805.8 2009-12-14
GBGB0921805.8A GB0921805D0 (en) 2009-12-14 2009-12-14 Drug composition and its use in therapy
PCT/GB2010/052085 WO2011073646A1 (en) 2009-12-14 2010-12-14 Combination of theobromine with a decongestant and its use for the treatment of cough

Publications (2)

Publication Number Publication Date
RU2012129839A true RU2012129839A (en) 2014-01-27
RU2564904C2 RU2564904C2 (en) 2015-10-10

Family

ID=41667045

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012129839/15A RU2564904C2 (en) 2009-12-14 2010-12-14 Theobromine-decongestant combination and application thereof for treating cough

Country Status (18)

Country Link
EP (1) EP2512464A1 (en)
JP (2) JP2013513651A (en)
CN (2) CN105816462A (en)
AU (1) AU2010332494B2 (en)
BR (1) BR112012014161A2 (en)
CA (1) CA2784214C (en)
CO (1) CO6541630A2 (en)
EC (1) ECSP12012132A (en)
GB (1) GB0921805D0 (en)
IL (1) IL220383A (en)
MX (1) MX343222B (en)
NZ (1) NZ600243A (en)
PE (1) PE20121537A1 (en)
RU (1) RU2564904C2 (en)
SG (2) SG10201408377QA (en)
UA (1) UA105944C2 (en)
WO (1) WO2011073646A1 (en)
ZA (1) ZA201204293B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9407414A (en) * 1993-09-07 1996-11-12 Procter & Gamble Compositions containing a non-steroidal propionic acid anti-inflammatory agent amino acid salt and at least one decongestant an expectorant an antihistamine and an antitussive
HUP9700654A2 (en) * 1997-03-26 1999-09-28 Dezső Korbonits Antitussive compositions containing theobromine
US6417206B1 (en) * 2001-01-26 2002-07-09 Medpointe Healthcare Inc. Antitussive/antihist aminic/decongestant compositions
JP2002308761A (en) * 2001-04-09 2002-10-23 Taisho Pharmaceut Co Ltd Antitussive agent for common cold
JP2003128549A (en) * 2001-08-15 2003-05-08 Rohto Pharmaceut Co Ltd Composition applicable to mucous membrane
JP4377564B2 (en) * 2002-05-02 2009-12-02 ロート製薬株式会社 Composition for internal use
RU2311919C2 (en) * 2002-12-30 2007-12-10 Каунсел Оф Сайнтифик Энд Индастриал Рисерч Development of anti-coughing and throat softening herbal composition
US20040202677A1 (en) * 2003-04-10 2004-10-14 Hopkins Kevin J. Method of enhanced regional body fat reduction
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
KR20080009994A (en) * 2006-07-25 2008-01-30 안국약품 주식회사 Compositions for treating of cough
CN100518775C (en) * 2007-03-16 2009-07-29 邓丽菊 Medicine composition for treating cough and asthma and preparation thereof

Also Published As

Publication number Publication date
AU2010332494A1 (en) 2012-06-14
IL220383A0 (en) 2012-08-30
CO6541630A2 (en) 2012-10-16
NZ600243A (en) 2013-07-26
SG10201408377QA (en) 2015-02-27
AU2010332494B2 (en) 2015-01-15
CA2784214C (en) 2018-01-09
BR112012014161A2 (en) 2016-05-17
JP2013513651A (en) 2013-04-22
EP2512464A1 (en) 2012-10-24
GB0921805D0 (en) 2010-01-27
CA2784214A1 (en) 2011-06-23
ECSP12012132A (en) 2012-09-28
JP2016040279A (en) 2016-03-24
RU2564904C2 (en) 2015-10-10
ZA201204293B (en) 2013-02-27
PE20121537A1 (en) 2012-12-21
MX343222B (en) 2016-10-28
WO2011073646A1 (en) 2011-06-23
MX2012006625A (en) 2012-10-05
IL220383A (en) 2017-01-31
CN105816462A (en) 2016-08-03
SG181686A1 (en) 2012-07-30
UA105944C2 (en) 2014-07-10
CN102740843A (en) 2012-10-17

Similar Documents

Publication Publication Date Title
DOP2006000057A (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
MX2010005631A (en) Novel cyclic hydrocarbon compounds for the treatment of diseases.
ECSP17000643A (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and Paracetamol.
CL2013000063A1 (en) A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process.
BR112012009376B8 (en) solid pharmaceutical composition comprising a sglt-2 inhibitor and its pharmaceutical dosage form
AR124500A2 (en) INCREASED BIOAVAILABILITY OF THE DRUG IN NALTREXONE THERAPY
EA201001577A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
RU2013121788A (en) HIV REPLICATION INHIBITORS
BRPI0906181A2 (en) "method for treating hyperproliferative dysfunction, pharmaceutical composition, use of a therapeutic combination in the manufacture of a medicament for treating cancer, article of manufacture for treating a hyperproliferative dysfunction, method for determining compounds to be used in combination for the treatment of cancer". cancer treatment and method for determining a therapeutic combination to be used for cancer treatment "
CR11510A (en) USE OF A GAMMA-SECRETASE INHIBITOR FOR CANCER TREATMENT
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
UY30819A1 (en) DERIVATIVES OF PIRAZOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
BRPI0517701A (en) use of a compound in the preparation of medicines for the treatment of diabetes mellitus
AR124497A2 (en) METHODS TO TREAT BINGE EATING OR COMPULSIVE EATING; USE OF BUPROPRION AND NALTREXONE TO PREPARE A MEDICATION FOR SUCH METHODS, AND PHARMACEUTICAL COMPOSITION
BRPI0922789A2 (en) albumin binding peptide for disease recognition
RU2012129839A (en) COMBINATION OF THEOBROMIN WITH DECONGESTANT AND ITS APPLICATION FOR TREATMENT OF COUGH
BR112012016783A2 (en) "Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy"
AR052830A1 (en) CLADRIBINE REGIME TO TREAT MULTIPLE SCLEROSIS
RU2008148597A (en) PHARMACEUTICAL COMBINATIONS
AR079000A1 (en) ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS
UY31826A (en) PEPTIDE COMPOUND AND ITS USE
BR112013025410A2 (en) therapeutic treatment

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171215